Pivotal Research Reiterates a Buy Rating on Omega Protein Corp.

By Carrie Williams

In a report issued on November 3, Timothy Ramey from Pivotal Research reiterated a Buy rating on Omega Protein Corp. (NYSE: OME), with a price target of $30. The company’s shares closed last Friday at $21.90.

According to TipRanks.com, Ramey is a 4-star analyst with an average return of 6.3% and a 53.2% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.

Omega Protein Corp. has an analyst consensus of Moderate Buy, with a price target consensus of $30.

Based on Omega Protein Corp.’s latest earnings report from June 30, the company posted quarterly revenue of $112.7M and quarterly net profit of $5.66M. In comparison, last year the company earned revenue of $112.2M and had a net profit of $10.57M.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2015, Gregory Toups, the VP Ch Acct Officer & Controlle of OME sold 1,115 shares for a total of $15,554.

Omega Protein Corp. is a nutritional ingredient which develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of foods, dietary supplements and animal feeds. The company produces and markets a variety of products produced from menhaden including regular grade and value-added specialty fish meals, crude and refined fish oils and fish solubles that are sold primarily to animal nutrition markets. The company operates its business through two segments: Animal Nutrition and Human Nutrition. The Animal Nutrition segment consists of two subsidiaries: Omega Protein, Inc. and Omega Shipyard, Inc. The Human Nutrition segment operates under the name Nutegrity. Omega Protein was founded by John A. Haynie and Thomas Haynie in 1878 and is headquartered in Houston, TX.